Novartis to Pay Up to $1 Billion to Matchpoint Therapeutics for Development of Oral Anti-Inflammatory Therapies
Gelonghui July 25 | Swiss pharmaceutical company Novartis will pay up to $1 billion to U.S.-based biotech firm Matchpoint Therapeutics for the development of oral medications targeting various inflammatory diseases. Matchpoint will use its technology to develop drugs that block the activity of specific proteins, helping to reduce the generation of inflammatory signals.
Summary
Swiss pharmaceutical giant Novartis has agreed to pay up to $1 billion to U.S.-based biotech firm Matchpoint Therapeutics to co-develop oral therapies targeting multiple inflammatory diseases. Matchpoint will leverage its proprietary covalent drug discovery platform to create small molecule inhibitors that block the activity of a specific transcription factor involved in inflammatory signaling pathways.